Advertisement

Pfizer Inc. PFE

Set alert

Price alert · PFE

All alert types
30.52 USD +0.57 +1.90%

At close · Oct 30

30.45 -0.07 -0.22%

After hours · Oct 30, 7:55 PM ET

Bid
30.50 × 16,800
Ask
30.52 × 4,900
30.14 Day range 30.65
23.67 52-week range 30.52
YTD
+22.57%
1 year
+25.65%
Open
30.51
Prev close
29.95
Mkt cap
173.95B
Vol
45.49M
Avg vol
33.75M
EPS
0.76
P/E
40.16
Div yield
5.74%
More statistics
Low
30.14
High
30.65
Forward P/E
10.58
Beta
0.28
Short ratio
4.20
Inst. own
69.06%
Dividend
1.72
Ex-div date
Nov 5, 2026
Earnings
Nov 3, 2026
50-d avg
28.49
200-d avg
26.77
1y target
29.26

5Y chart

Chart tools
Interval

Events in this range
  • Nov 4, 2021Dividend: 0.39
  • Jan 27, 2022Dividend: 0.4
  • May 12, 2022Dividend: 0.4
  • Jul 28, 2022Dividend: 0.4
  • Nov 3, 2022Dividend: 0.4
  • Dec 5, 2022Dividend: 0.4
  • Jan 26, 2023Dividend: 0.41
  • May 11, 2023Dividend: 0.41
  • Jul 27, 2023Dividend: 0.41
  • Nov 9, 2023Dividend: 0.41
  • Nov 10, 2023Dividend: 0.41
  • Jan 25, 2024Dividend: 0.42
  • Jan 26, 2024Dividend: 0.42
  • May 9, 2024Dividend: 0.42
  • Jul 25, 2024Dividend: 0.42
  • Jul 26, 2024Dividend: 0.42
  • Nov 8, 2024Dividend: 0.42
  • Jan 24, 2025Dividend: 0.43
  • May 9, 2025Dividend: 0.43
  • Jul 25, 2025Dividend: 0.43
  • Aug 5, 2025Earnings: 0.78; estimate 0.58; surprise 34.48%
  • Nov 4, 2025Earnings: 0.87; estimate 0.633; surprise 37.44%
  • Nov 7, 2025Dividend: 0.43
  • Jan 23, 2026Dividend: 0.43
  • Feb 3, 2026Earnings: 0.66; estimate 0.567; surprise 16.4%
  • May 5, 2026Earnings: 0.75; estimate 0.722; surprise 3.88%
  • May 8, 2026Dividend: 0.43
  • Jul 13, 2026Rating: BMO Capital · Outperform → Outperform
  • Jul 24, 2026Dividend: 0.43
  • Aug 4, 2026Earnings: 0.77; estimate 0.682; surprise 12.9%
  • Aug 7, 2026Rating: Guggenheim · Buy → Buy
  • Sep 10, 2026Rating: HSBC · Hold → Hold
  • Oct 6, 2026Rating: Scotiabank · Sector Outperform → Sector Outperform
  • Oct 8, 2026Rating: Cantor Fitzgerald · Neutral → Neutral
  • Oct 9, 2026Rating: JP Morgan · Neutral → Neutral
  • Nov 3, 2026Earnings: —; estimate 0.729; surprise —%
Signals (86)
NameDateAgo
MACD: Buy SignalAug 10, 20262 months ago
SMA: BullishAug 3, 20263 months ago
SMA: BullishAug 3, 20263 months ago
SMA: BearishMay 4, 20266 months ago
MACD: Sell SignalApr 27, 20266 months ago
SMA: BearishApr 20, 20266 months ago
SMA: BullishApr 13, 20266 months ago
SMA: BearishApr 6, 20266 months ago
SMA: BullishMar 16, 20267 months ago
SMA: BearishMar 9, 20267 months ago
SMA: BullishJan 5, 202610 months ago
SMA: BearishDec 22, 202510 months ago
SMA: BullishNov 10, 202511 months ago
SMA: BearishOct 6, 20251 year ago
SMA: BullishSep 29, 20251 year ago
SMA: BullishSep 29, 20251 year ago
SMA: BearishSep 8, 20251 year ago
SMA: BearishAug 25, 20251 year ago
SMA: BullishAug 4, 20251 year ago
SMA: BearishJul 28, 20251 year ago
SMA: BearishJul 28, 20251 year ago
SMA: BullishJul 21, 20251 year ago
SMA: BearishJul 14, 20251 year ago
SMA: BullishJun 30, 20251 year ago
MACD: Buy SignalJun 2, 20251 year ago
SMA: BullishMay 26, 20251 year ago
RSI: OversoldApr 7, 20251 year ago
MACD: Sell SignalMar 31, 20251 year ago
SMA: BearishMar 24, 20251 year ago
SMA: BullishMar 17, 20251 year ago
SMA: BearishMar 10, 20251 year ago
SMA: BullishFeb 17, 20251 year ago
MACD: Buy SignalFeb 17, 20251 year ago
SMA: BearishFeb 3, 20251 year ago
MACD: Sell SignalFeb 3, 20251 year ago
SMA: BullishJan 27, 20251 year ago
MACD: Buy SignalJan 27, 20251 year ago
SMA: BearishJan 20, 20251 year ago
SMA: BullishDec 23, 20241 year ago
SMA: BearishOct 28, 20242 years ago
SMA: BearishOct 21, 20242 years ago
MACD: Sell SignalOct 21, 20242 years ago
SMA: BullishOct 7, 20242 years ago
SMA: BearishSep 23, 20242 years ago
SMA: BearishAug 5, 20242 years ago
SMA: BullishJul 8, 20242 years ago
SMA: BearishJul 1, 20242 years ago
SMA: BullishJun 17, 20242 years ago
SMA: BullishJun 17, 20242 years ago
SMA: BearishJun 10, 20242 years ago
SMA: BearishJun 10, 20242 years ago
SMA: BullishMay 13, 20242 years ago
SMA: BullishApr 29, 20242 years ago
SMA: BearishApr 1, 20242 years ago
SMA: BullishMar 25, 20242 years ago
SMA: BearishMar 18, 20242 years ago
SMA: BullishMar 11, 20242 years ago
SMA: BearishJan 8, 20242 years ago
SMA: BullishJan 1, 20242 years ago
MACD: Buy SignalJan 1, 20242 years ago
RSI: OversoldNov 27, 20232 years ago
RSI: OversoldNov 6, 20232 years ago
RSI: OversoldOct 9, 20233 years ago
MACD: Sell SignalSep 18, 20233 years ago
RSI: OversoldSep 18, 20233 years ago
SMA: BearishJun 19, 20233 years ago
SMA: BullishJun 5, 20233 years ago
MACD: Buy SignalJun 5, 20233 years ago
RSI: OversoldMay 8, 20233 years ago
RSI: OversoldMar 6, 20233 years ago
MACD: Sell SignalJan 23, 20233 years ago
SMA: BearishJan 9, 20233 years ago
SMA: BearishJan 9, 20233 years ago
SMA: BullishNov 21, 20223 years ago
MACD: Buy SignalOct 31, 20224 years ago
SMA: BullishOct 24, 20224 years ago
MACD: Sell SignalAug 22, 20224 years ago
SMA: BearishJul 18, 20224 years ago
SMA: BearishJul 11, 20224 years ago
SMA: BullishJul 4, 20224 years ago
SMA: BullishJun 20, 20224 years ago
SMA: BearishJun 6, 20224 years ago
SMA: BearishJun 6, 20224 years ago
SMA: BullishMay 16, 20224 years ago
SMA: BearishApr 18, 20224 years ago
SMA: BullishMar 14, 20224 years ago

Key statistics

Market cap
173.87B
Enterprise value
222.78B
Trailing P/E
40.14
Forward P/E
10.58
PEG ratio
13.72
Price / sales
2.73
Price / book
2.04
EPS (TTM)
0.76
Beta
0.28
Dividend yield
5.74%
Payout ratio
226.32%
Profit margin
6.80%
Revenue (TTM)
63.70B
Revenue growth
2.60%
Free cash flow
12.49B
Total cash
11.70B
Total debt
63.48B
Return on equity
5.01%
Shares outstanding
5.70B
Short % of float
2.42%
50-day average
28.49
200-day average
26.77

Analyst view

Consensus: buy

Buy
Price target (mean) 29.26 -4.1% downside
Target (low)
25.00
Target (mean)
29.26
Target (high)
36.00
Ratings (0m) 28 9 buy · 17 hold · 2 sell
  • Strong buy1
  • Buy8
  • Hold17
  • Sell1
  • Strong sell1

Next earnings

Nov 3, 2026

Expected Nov 3, 2026. Consensus EPS estimate 0.72803.

Earnings history

Financials — quick view

All financials
PFE Revenue — quarterly 15.03B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
PFE Net income — quarterly -247.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
PFE EPS — quarterly -0.04
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

PFE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 3, 2026Sep 28, 20260.729———
Aug 4, 2026Jun 28, 20260.6820.77+0.09+12.90%
May 5, 2026Mar 29, 20260.7220.75+0.03+3.88%
Feb 3, 2026Dec 31, 20250.5670.66+0.09+16.40%
Nov 4, 2025Sep 28, 20250.6330.87+0.24+37.44%
Aug 5, 2025Jun 29, 20250.580.78+0.20+34.48%

Upgrades / downgrades

PFE analyst upgrades and downgrades
DateFirmActionFromTo
Oct 9, 2026JP MorganmainNeutralNeutral
Oct 8, 2026Cantor FitzgeraldmainNeutralNeutral
Oct 6, 2026ScotiabankmainSector OutperformSector Outperform
Sep 10, 2026HSBCmainHoldHold
Aug 7, 2026GuggenheimmainBuyBuy
Jul 13, 2026BMO CapitalmainOutperformOutperform

About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
pfizer.com

News

Your note

Sign in to keep a note on PFE — it syncs with the Stock Master app.

Insider holders

PFE insider holders
InsiderRelationLatest transactionDateShares held
BLAYLOCK RONALD EDirectorPurchaseAug 4, 202671,688
BOSHOFF CHRISTOFFELOfficerStock Award(Grant)Feb 24, 2026162,088
BOURLA ALBERTChief Executive OfficerPurchaseAug 11, 2026435,555
BUCKLEY MORTIMER J.DirectorPurchaseAug 4, 202637,632
DAMICO JENNIFER B.OfficerSaleAug 4, 202628,611
FONSECA LIDIA PH.D.OfficerConversion of Exercise of derivative securityFeb 24, 202646,455

Institution ownership

PFE institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.29%529,670,43316.16BJun 29, 2026
Vanguard Capital Management LLC6.53%372,149,85211.35BJun 29, 2026
State Street Corporation5.39%307,090,8979.37BJun 29, 2026
Geode Capital Management, LLC2.37%135,275,7824.13BJun 29, 2026
Vanguard Portfolio Management LLC2.09%119,235,0303.64BJun 29, 2026
Fisher Asset Management, LLC1.91%109,067,2913.33BJun 29, 2026

Fund ownership

PFE fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%180,944,8985.52BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%147,700,0664.51BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%75,946,8892.32BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%73,983,9032.26BAug 30, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%70,581,6112.15BSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Value Index Fund0.95%54,248,0961.65BJun 29, 2026
Advertisement